Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reiterated by Cowen and Company in a research note issued to investors on Friday. They presently have a $70.00 target price on the stock. Cowen and Company’s price target indicates a potential upside of 24.87% from the company’s previous close.

Other research analysts have also recently issued reports about the company. UBS AG raised their price objective on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price objective on Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and issued a $72.00 price objective on shares of Merck & in a report on Friday, September 8th. Citigroup Inc. upgraded Merck & from a “neutral” rating to a “buy” rating and set a $72.00 target price on the stock in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $67.07.

Merck & (MRK) traded up $0.72 on Friday, hitting $56.06. The stock had a trading volume of 9,799,072 shares, compared to its average volume of 12,174,160. The firm has a market capitalization of $151.45 billion, a P/E ratio of 14.23 and a beta of 0.78.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period in the prior year, the business posted $1.07 EPS. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. equities analysts predict that Merck & will post 3.95 earnings per share for the current fiscal year.

WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/03/cowen-and-company-reiterates-hold-rating-for-merck-company-inc-mrk.html.

Several institutional investors have recently made changes to their positions in MRK. Mycio Wealth Partners LLC grew its stake in shares of Merck & by 20.9% during the first quarter. Mycio Wealth Partners LLC now owns 20,235 shares of the company’s stock valued at $1,286,000 after acquiring an additional 3,495 shares in the last quarter. Cubic Asset Management LLC lifted its holdings in Merck & by 2.3% in the first quarter. Cubic Asset Management LLC now owns 13,250 shares of the company’s stock worth $842,000 after acquiring an additional 300 shares during the last quarter. Dubuque Bank & Trust Co. lifted its holdings in Merck & by 19.9% in the first quarter. Dubuque Bank & Trust Co. now owns 47,488 shares of the company’s stock worth $3,017,000 after acquiring an additional 7,892 shares during the last quarter. Delta Asset Management LLC TN lifted its holdings in Merck & by 2.6% in the first quarter. Delta Asset Management LLC TN now owns 12,499 shares of the company’s stock worth $794,000 after acquiring an additional 316 shares during the last quarter. Finally, Duncker Streett & Co. Inc. raised its holdings in shares of Merck & by 6.1% during the first quarter. Duncker Streett & Co. Inc. now owns 53,537 shares of the company’s stock valued at $3,402,000 after buying an additional 3,091 shares during the last quarter. Institutional investors own 72.86% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.